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Abstract
The relationship between a screening tests’ positive predictive value,
ρ, and its target prevalence, φ, is proportional - though not linear in
all but a special case. In consequence, there is a point of local extrema
and maximum curvature defined only as a function of the sensitivity
a and specificity b beyond which the rate of change of a test’s ρ drops
at a differential pace relative to φ. Herein, we show the mathematical
model exploring this phenomenon and define the prevalence threshold
φe point where this change occurs as:
φe =
√
a(−b+1)+b−1
(ε−1)
where ε = a+b. From the prevalence threshold we deduce a more gen-
eralized relationship between prevalence and positive predictive value
as a function of ε, which represents a fundamental theorem of screen-
ing, herein defined as:
limε→2
∫ 1
0
ρ(φ)dφ = 1
Understanding the concepts described in this work can help contex-
tualize the validity of screening tests in real time, and help guide the
interpretation of different clinical scenarios in which screening is un-
dertaken.
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1 Screening tests
Screening is defined as the presumptive identification of unrecognised
disease in asymptomatic individuals by means of tests, examinations or pro-
cedures [Wilson et al., 1968]. The ultimate purpose of a screening test is
two-fold: 1) to allow for the early detection of a disease, and thus establish
a surveillance plan to assess progression, or 2) to detect a condition early in
order to treat it most effectively. Screening tests are not considered diagnos-
tic, but are used to identify a subset of the population that should undergo
additional testing in order to accurately establish the absence or presence
of disease [Sackett, 1975].
2 Health conditions amenable to screening
In 1968, the World Health Organization (WHO) published guidelines on
the principles and practice of screening for disease, which are often referred
to as the Wilson− Jungner criteria [Andermann et al., 2008]. These prin-
ciples are still broadly applicable today and include the following: 1) The
condition should be an important health problem. 2) There should be a
treatment for the condition. 3) Facilities for diagnosis and treatment should
be available. 4) There should be a latent stage of the disease. 5) There
should be a screening test or examination for the condition. 6) The test
should be acceptable to the population. 7) The natural history of the dis-
ease should be adequately understood. 8) There should be an agreed policy
on whom and when to treat. 9) The total cost of finding a case should
be economically balanced in relation to medical expenditure as a whole.
Finally, 10) Case-finding should be a continuous process.
3 Disease progression and screening
In the disease process, the biological onset of disease is followed by clini-
cal symptoms, then diagnosis and therapy until there is an outcome, includ-
ing survival or death [Herman, 2006]. The time from the onset of disease
until clinical symptoms occur is known as the pre-clinical phase. The indi-
vidual has the disease but doesn’t know it. The clinical phase is the latter
part of the process, from the occurrence of clinical symptoms through ther-
apy and outcome[Herman, 2006]. Within the preclinical phase, there may
be an interval between the onset of the disease and the occurrence of clinical
symptoms during which disease can be detected with certain screening tests.
This is called a detectable pre-clinical, or latent, phase. If treatment is more
effective when disease is in the preclinical stage, as is the case for most con-
ditions, screening for disease during the detectable pre-clinical phase offers
an advantage[Herman, 2006].
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Figure 1. Natural Progression of Disease
4 Effectiveness and validity of screening tests
When conducting a screening test, 4 different parameters help to deter-
mine its overall ability to correctly identify individuals with the disease in
question [Brenner and Gefeller, 1997]. These include the sensitivity a, speci-
ficity b, positive predictive value ρ and negative predictive value σ. Sensitiv-
ity refers to the proportion of affected individuals that have a positive test
(true positive rate), and specificity refers to the proportion of unaffected in-
dividuals that have a negative test (true negative rate). On the other hand,
the positive predictive value (ρ) is defined as the percentage of patients with
a positive test that do in fact have the disease, and conversely, the negative
predictive value (φ) refers to the percentage of patients with a negative test
that do not have the disease. To further explore these properties in detail,
we draw a 2 x 2 table as follows:
Table 1. 2x2 Table
Condition
Present Absent
Positive Test True Positive (α) False Positive (β)
Negative Test False Negative (γ) True Negative (δ)
Where the following variables are thus defined:
prevalence = φ = [α+ γ/α+ β + γ + δ],
sensitivity = a = [α/α+ γ],
specificity = b = [δ/δ + β],
PPV = ρ = [α/α+ β],
NPV = σ = [δ/γ + δ].
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5 Bayes’ Theorem
Bayes’ Theorem describes the probability of an event based on prior
knowledge of conditions related to that specific event [Moons et al., 1997].
Mathematically speaking, the equation translates to the conditional proba-
bility of an event A given the presence of an event or state B. As per Bayes’
Theorem, the above relationship is equal to the probability of event B given
event A, multiplied by the ratio of independent probabilities of event A to
event B. Simply stated, the equation is written as follows:
P (A|B) = P (B|A)P (A)
P (B)
(1)
Where A, B = events, P (A|B) = probability of A given B is true, P (B|A)
= probability of B given A is true, and P(A) and P(B) are the independent
probabilities of A and B. If we use T +/- as either a positive or negative
test, and denote D +/- as the presence or absence or disease then we can
use Bayes’ theorem to calculate the positive predictive value by asking the
following question: given a positive screening test, what is the probability
that such individual does in fact have the disease in question?
P (D + |T+) = P (T + |D+)P (D+)
P (T + |D+)P (D+) + P (T + |D−)P (D−) (2)
Since the probability of not having the disease is equal to the complement
of the prevalence and the false positive rate is equal to the complement of
the specificity, Bayes’ theorem yields the PPV as follows:
ρ(φ) =
aφ
aφ+ (1− b)(1− φ) =
aφ
aφ+ bφ− b− φ+ 1 (3)
where ρ(φ) = PPV, a = sensitivity, b = specificity and φ = prevalence.
We have thus shown that the PPV, ρ, is a function of prevalence, φ.
As the prevalence increases, the ρ(φ) also increases but the NPV, σ(φ),
decreases and vice-versa.
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By the above equation, we obtain:
lim
φ→1
ρ(φ) = 1 (4)
and,
lim
φ→0
ρ(φ) = 0 (5)
Inversely, we can isolate the prevalence as a function of sensitivity, speci-
ficity and the PPV as follows:
φ =
1 + b
a
ρ
− a− b+ 1 (6)
6 Properties of Screening Curves
Screening curves come in two forms: one prevalence-independent relat-
ing the sensitivity to the specificity, also known as the receiver operating
characteristc (ROC) curve, and one prevalence-dependent relating a tests’
positive predictive value to its target disease’s prevalence. The latter screen-
ing curves are continuous, positive functions in the real plane, whose domain
spans 0 < φ < 1 and cross the spectrum boundaries at coordinates [0,0] and
[1,1]. The relationship between φ and ρ is proportional and as such, these
curves retain their concavity or convexity throughout the domain.
7 The Screening Paradox
If a disease process is recognized and treated early, and a diagnosis
is therefore prevented, the prevalence of such disease would drop in the
population, which as per Bayes’ theorem, would make the tests’ predictive
value drop in return [Smith et al., 2000]. Put another way, assuming cu-
rative/preventative treatment following an abnormal screening test exists,
a very powerful screening test would, by performing and succeeding at the
very task it was developed to do, paradoxically reduce its ability to cor-
rectly identify individuals with the disease it screens for in the future. Now,
this paradoxical effect tends to be well tolerated by the system up to a well
defined prevalence point beyond which the geometry of the screening curve
changes most drastically. Technically speaking, there is a prevalence level
below which the rate of change of a test’s ρ drops at a differential pace rel-
ative to φ. In order to explore this notion further, we define a new entity
henceforth known as the screening coefficient, ε.
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8 The Screening Coefficient (ε)
To preface this section, we hereby define a new entity, the screening co-
efficient (ε), as the sum of sensitivity a and specificity b.
ε = a+ b→ [ε ∈ IR|0 < ε < 2] (7)
We know from equation (3) that an increase in prevalence will bring about
an increase in the PPV (and vice-versa) at different velocities depending on
the prevalence level. We can calculate this velocity by taking the first order
derivative of equation (3) as follows:
dρ
dφ
=
a(1− b)
(aφ+ (1− b)(1− φ))2 (8)
Since both φ and ρ are positive real numbers between 0 and 1, dρ/dφ is a
positive real number as well as per equation (8). This implies that the re-
lationship between φ and ρ is directly proportional throughout the interval
[0 - 1] ∈ IR. However, in order to determine whether the rate at which the
PPV is changing with respect to prevalence is accelerating or decelerating,
we take the second order derivative of equation (3) as follows:
d2ρ
dφ2
= −2a (−b+ 1) (a− 1 + b)
(aφ+ (1− b) (1− φ))3 (9)
From equation (9) it follows that when:
ε < 1⇒ d
2ρ
dφ2
> 0 (10)
ε > 1⇒ d
2ρ
dφ2
< 0 (11)
ε = 1⇒ d
2ρ
dφ2
= 0 (12)
We thus note that the value of ε determines the concavity or convexity of
the screening curve.
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8.1 Hypothethical scenario
Condition X is a disease present in a population. It has a preclinical
phase and is amenable to screening. Test X is the screening test developed
to detect the latent phase of Condition X. Test X therefore has all of the
pertinent screening parameters - sensitivity, specificity, and negative and
positive predictive values. If condition X has a high prevalence in the pop-
ulation (e.g. hyperlipidemia, hypertension, diabetes, endemic infections,
amongst others) and ε >1, then significant drops in prevalence will not
bring about significant drops in PPV until prevalence drops below a certain
threshold, which for cases of ε >1, occurs at low prevalence levels. It thus
follows that in cases like this, the screening tests detection ability remains
relatively stable until it has significantly helped drop the prevalence. On
the other hand, if condition X has a high prevalence in the population and
ε <1, then small drops in prevalence will bring about significant drops in
PPV until prevalence drops below a certain threshold at a high prevalences.
8.2 Figure 2. Graphic representation of ρ(φ) as function of ε
0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
ε >1
φ
ρ
(φ
)
ρ(φ)
dρ/dφ
ρ = 1
0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
ε <1
φ
ρ
(φ
)
ρ(φ)
dρ/dφ
ρ = 1
The first graph represents scenarios where ε > 1. The second graph
represents scenarios where ε < 1. The sensitivity and specificity are
constant and were randomly chosen to satisfy the ε condition.
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9 Derivation of the radius of curvature of ρ(φ)
In order to determine the radius of curvature of the φ(ρ) graph at any
given point M, we consider a circle with radius R, which is perpendicular
to the tangent line of the function at that point. We consider an adjacent
point increment by dφ and draw another tangent line to this point N, which
we join to the center of the circle with radius R. As such, an arc of length
dS is formed, which in turn creates an angle ϕ between M and N. These
variables see the following properties:
tan(ϕ) =
dρ
dφ
(13)
dS = Rdϕ =
√
1 + (
dρ
dφ
)2dφ (14)
From equalities (13) and (14), the differential equation follows:
d
dφ
tan(ϕ) =
d
dφ
(
dρ
dφ
) =
d2ρ
dφ2
(15)
From the trigonometric identity 1 + tan2(ϕ) = sec2(ϕ), it follows that:
d
dφ
tan(ϕ) = sec2(ϕ)
dϕ
dφ
=
d2ρ
dφ2
(16)
Therefore,
(1 + tan2(ϕ))
dϕ
dφ
=
d2ρ
dφ2
(17)
Since tan(ϕ) = dρ/dφ, equation (17) becomes:
(1 + (
dρ
dφ
)2)
dϕ
dφ
=
d2ρ
dφ2
(18)
Isolating dϕ/dφ, we obtain:
dϕ
dφ
=
d2ρ
dφ2
(1 + ( dρ
dφ
)2)
(19)
8
Using equation (14) this relationship then becomes:
R
d2ρ
dφ2
(1 + ( dρ
dφ
)2)
=
√
1 + (
dρ
dφ
)2 (20)
Finally, isolating the radius of curvature R:
R =
[1 + ( dρ
dφ
)2]
3
2
| d2ρ
dφ2
| (21)
The radius of curvature R is inversely proportional to the curvature κ:
R =
1
κ
⇒ κ = |
d2ρ
dφ2
|
[1 + ( dρ
dφ
)2]
3
2
(22)
Now that we know what the curvature function κ is, we can determine
where the curvature of φ(ρ) falls at a maximum. Practically speaking, this
represents the point of sharpest change in dρdφ , known as the extrema. In
order to do so, we find the derivative of the κ function and determine its
roots:
dκ
dφ
= 0 ↪→ {φe, ρe} (23)
The above equation yields the value of φ where the maximum curvature
κ and thus a minimum radius of curvature R exist. We define this point
as the point of local extrema [φe, ρe] of the ρ(φ) function. On the other
hand, the inflection point [φi, ρi] is a point on a curve at which the sign of
the curvature (i.e., the concavity) changes. The points of local extrema are
distinguishable from the inflection point only in that the curvature function’s
second order-derivative equals 0:
d2κ
dφ2
= 0 ↪→ {φi, ρi} (24)
However, as we described in Section 6, given the proportionality between
φ and ρ all screening curves retain their concavity/convexity throughout the
domain [0,1].
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9.1 What does the point of local extrema (φe, ρe) tell us?
The point of local extrema φe, ρe denotes the point of maximum curva-
ture of the function ρ(φ) throughout the prevalence spectrum. Practically
speaking, it tells us where the sharpest turn, or change, in PPV as a function
of prevalence occurs. In cases of ε < 1 the sharp increase occurs at higher
prevalence levels with lower PPV levels. On the other hand, when ε > 1 the
sharp increase occurs at lower prevalence levels with higher PPV levels.
9.2 How is φe determined?
By equating equation (22) to 0 and looking for its roots, we re-arrange
the terms and the above expression simplifies to:
1 = −a
2 (−b+ 1)2 + (aφ+ (−b+ 1) (−φ+ 1))4
2 (aφ+ (−b+ 1) (−φ+ 1))4 (25)
(aφ+ (−b+ 1) (−φ+ 1))4 = −a2 (−b+ 1)2 (26)
Taking the fourth root of both sides, we obtain:
(aφ+ bφ− b− φ+ 1) = ±
√
a (−b+ 1) (27)
Expanding and isolating φ while taking the positive value of the root,
we obtain:
φe =
√
a (−b+ 1) + b− 1
(a+ b− 1) =
√
a (−b+ 1) + b− 1
(ε− 1) (28)
This is the value of prevalence where the point of local extrema φe is
found. We denote this value of φ as the prevalence threshold. By plugging
φe into equation (3) we obtain its corresponding ρe value. Note the inverse
relationship between φe and ε.
φe ∼ 1
ε
(29)
It is critical to understand that an identical value of ε can provide sig-
nificantly different prevalence thresholds since sensitivites and specificities
do not respect commutative laws in this context.
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9.3 Area Under the Curve ρ(φ)
While the curvature κ and the point of local extrema φe, ρe provide a
quantitative determination of the prevalence threshold, we can establish a
qualitative determination of this statistic as well, which is far more intu-
itive. We can calculate the area under the curve (AUC) of ρ(φ) by integrat-
ing through the function’s domain between [0,0] and [1,1]. Intuitively, the
greater the area, the greater ε must be and vice-versa.
∫ 1
0
ρ(φ)dφ =
a ((b− 1) ln (|(b+ a− 1)φ− b+ 1|) + (b+ a− 1)φ)
(a+ b− 1)2
(30)
It thus follows that:
lim
ε→2
∫ 1
0
ρ(φ)dφ = 1 (31)
We deduce that as ε approaches its maximum possible value of 2, the
AUC of φ(ρ) goes to 1. As equation (31) describes the relationship between
all of the pertinent parameters of a positive screening test as a function
of prevalence, we define the latter as a fundamental theorem of screening.
Since we know from equation (29) that the φe is inversely proportional to ε,
we infer that the greater the AUC, the lower the prevalence threshold and
vice-versa.
9.4 Clinical Corollaries
All screening parameters are fundamental to the understanding of the
value of screening tests, their limitations, and the concepts thus far described
in this work. That said, we can consider the predictive values ρ(φ) to be
most consequential to the individual clinician over the other parameters.
Why is ρ(φ) a more critical parameter for the clinician than sensitivity and
specificity? This is simply because the interpretation of predictive values
is done at the level of a single test result, among individuals in whom a
diagnosis has not yet been made, and whose ultimate diagnostic status is
therefore unknown. In the case of sensitivity and specificity, the ultimate
diagnostic status in the patient must be known a priori in order to determine
whether a particular screening test is sensitivity and/or specific. As such,
chronologically speaking, since screening tests lead to eventual diagnoses,
the interpretation of a test must occur before a diagnosis is made.
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Figure 3. Sample screening curves as a function of ε
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These are a random sample of combinations of ε values calculated from
random sensitivities and specificities, and their corresponding prevalence
threshold (φe) values. To obtain the prevalence at which the threshold is
crossed, multiply the values in red by 10. φe is undefined in the special
case where the geometry of the screening curve becomes linear as a
consequence of ε equalling 1.
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10 Conclusion
The curvilinear relationship between a screening test’s positive predic-
tive value and its target disease prevalence is proportional. In consequence,
there is an inflection point of maximum curvature in the screening curve
defined as a function of the sensitivity and specificity beyond which the rate
of change of a test’s PPV declines sharply relative to disease prevalence.
Herein, we demonstrate a mathematical model exploring this phenomenon
and define the prevalence threshold point where this change occurs. To
the best of our knowledge, while this concept is a simple consequence of
Bayes’ theorem and the natural shape of screening curves, it has never been
properly defined mathematically as showcased in this work. The prevalence
threshold can help contextualize the validity of a screening test in real time,
thereby enhancing our understanding of the dynamics and epidemiology of
specific conditions. This concept can help clarify the inherent limitations of
screening tests at large, namely, that beyond a well-defined point, the posi-
tive predictive value of screening tests will drop, as individuals are treated
and the prevalence drops in turn. This concept allows for the calculation
of that threshold point simply using a tests’ sensitivity and specificity. Fi-
nally, this simple equation can be applied to any and all screening test whose
sensitivity, specificity and target prevalence are known.
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10.1 Addendum - Example of SARS-CoV-2 Pandemic
The current COVID-19 pandemic provides an excellent opportunity to
apply the methods herein described. The nasal swab PCR screening test
for COVID-19 has been shown to have a high analytical sensitivity of 95
percent limit of detection (LOD) for the RNA-dependent RNA polymerase
(RdRP) gene. Likewise, the test is 99 percent specific for SARS-CoV-2 when
tested against 31 common respiratory pathogens [Cheng et al., 2020]. We
thus draw the screening curve for this test ρ(φ):
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)
ε = 1.94
We calculate the prevalence threshold φe by using equation (28), with
values for a = 0.95, b = 0.99 and ε = 1.94. We obtain:
φe =
√
a (−b+ 1) + b− 1
(ε− 1) =
√
.95 (−.99 + 1) + .99− 1
(1.94− 1) = .093 (32)
As noted in the figure above, significant drops in prevalence only marginally
impact the PPV until the prevalence threshold is reached. In other words,
when the prevalence of active COVID-19 cases drops below 9.3 percent, the
nasal RT-PCR test’s PPV drops significantly faster. Since 9.3 percent of the
population has thankfully not been infected at any given time, we deduce
that a significant proportion of the current positive asal RT-PCR tests are
false positives. This simple fact can have significant economic, social and
administrative consequences as well as implications for the development of
epidemiologic models studying this disease.
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